Clinical Trials

Open for Recruitment:

Patients with bladder cancer who will undergo treatment with Atezolizumab: Principal Investigator - Dr. Larry Fong at UCSF
This is a single-center cross-sectional imaging study in patients with localized bladder cancer undergoing neoadjuvant atezolizumab, and patients with locally advanced or metastatic bladder cancer receiving standard of care (SOC) atezolizumab. Study participants will undergo whole body PET(Positron Emission Tomography)/MR(Magnetic Resonance) imaging with VisAcT/[18F]F-AraG prior to initiating atezolizumab and at a timepoint post initiation of atezolizumab treatment.

Patients with squamous cell carcinoma of the head and neck who will undergo treatment with anti-PD-1 treatment: Principal Investigator - Dr. Dimitri Colevas at Stanford University
This is a single-center cross-sectional imaging and correlative biomarker study in patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN). Cohort 1 will be patients with unresectable or metastatic SCCHN cancer receiving standard of care (SOC) anti-PD-1 treatment and Cohort 2 will be neoadjuvant study participants who will receive one dose of anti-PD-1 treatment prior to tumor resection or radiation. Patients will undergo two whole body PET(Positron Emission Tomography)/CT(Computed Tomography) imaging with VisAcT/[18F]F-AraG. First scan prior to initiating anti-PD-1 treatment and second scan post initiation of anti-PD-1 treatment.

Patients with solid tumors eligible to undergo immunotherapy treatment: Principal Investigator - Dr. Henry VanBrocklin at UCSF
This is an exploratory study to assess the biodistribution and radiation dosimetry of VisAcT/[18F]FAraG in cancer patients selected for immunotherapy. Each patient may have up to two PET(Positron Emission Tomography) imaging sessions - a baseline image and a scan post start of immunotherapy.

Not Yet Open for Recruitment:

Patients with localized non small cell lung cancer undergoing immunotherapy with or without stereotactic radiation therapy: Prinicpal Investigator - Dr. Ben Franc at UCSF
This is a single-center cross-sectional imaging study in patients with localized non-small cell lung cancer (NSCLC) and is part of the companion clinical trial (NCT03217071; Pembrolizumab with and without radiotherapy). Study participants will undergo a single whole body PET(Positron Emission Tomography)/CT (computed tomography) scan with VisAcT/[18F]F-AraG. The companion trial is for patients with stage I-IIIA NSCLC who will receive two cycles of systemic immunotherapy (pembrolizumab, a PD-1 inhibitor) with or without immune-priming stereotactic radiation therapy to the lateral half of the primary lung tumor prior to resection.

Completed Studies:

Healthy volunteers to study kinetics, dosimetry and safety of VisAcT: Prinicpal Investigator - Dr. Henry VanBrocklin at UCSF
The goal of this study was to visualize biodistribution of VisAcT/[18F]F-AraG through time in healthy human volunteers.